Faron Pharmaceuticals Ltd. (“Faron” or “the Company”) Faron Presents Full Analysis of Positive Phase 2 Interim Data from BEXMAB Trial at the 66th American Society of Hematology (ASH) Annual Meeting Poster highlights Overall response rate of 80% (16 out of 20) in refractory or relapsed HMA…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.